Aller au contenu principal

Hemogenyx is a pre-clinical stage biopharmaceutical group ( developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Its main product candidates include:

1. CDX bispecific antibody for the treatment of relapsed/refractory AML and conditioning of bone marrow transplants.

2. Lupus model as a platform for the discovery of novel treatments for lupus and other autoimmune diseases. 

3. Advanced peripheral blood Hematopoietic Chimera (AHC) – a platform technology for drug discovery and validation based on a proprietary type of humanized mice.

4. Broadly neutralizing antibodies for combating emerging infections – bio-protection/biodefense. 

5. Hu-PHEC – a novel source of transplantable blood stem cells.

Aires thérapeutiques
Catégorie de membre